Pharmaceutical Industry

P. Maréchal 

Tartegnin · Since 1988

Synbias Pharma AG 

Schaffhausen · Since 2012

3T Biosciences Europe GmbH 

Basel · Since 2022

The core activity of 3T Biosciences is the development of immunotherapies, specifically the identification and validation of T-cell receptor targets and specificities for the treatment of cancer and other immune-mediated diseases. The company utilizes its proprietary 3T-TRACE platform technology, which is based on machine learning algorithms and diverse target libraries.

4U pharma gmbh 

Herisau · Since 2019

The core activity of 4UPharma is the development, manufacturing and marketing of dietary supplements and health products for babies, children, pregnant women and adults, particularly in the area of immune system support, allergy and infection prevention.

A2A Pharma AG 

Rotkreuz · Since 2021

The core activity of a2a pharma is providing consulting services to companies in the pharmaceutical industry. The services include, among others, strategic consulting, market entry support, competitive analysis, and business development. The company supports its customers in accessing regulated markets and helps them find suitable products, brands, or business partners.

Aalto Pharma AG 

Baar · Since 2022

Aalto Pharma AG is a Swiss pharmaceutical company focused on supramolecular API delivery for treating topical infections in humans and animals. The company develops and manufactures supramolecular molecules and a patented delivery platform, which the website describes as non-toxic, non-comedogenic and non-cauterising, and reports bactericidal activity against antibiotic-resistant bacteria such as E. coli, A. baumannii and P. aeruginosa.

ABBA Therapeutics AG 

Basel · Since 2015

ABBA Therapeutics AG is a biopharmaceutical company specialized in mechanisms of cancer and the development of novel antibody medicines for cancer immunotherapy. The company researches protein targets related to immune checkpoints and develops therapeutic antibodies; a PCT patent application has been submitted for antibodies against one of its targets.

Abbott Laboratories GmbH 

Allschwil · Since 1989

Abbott Laboratories GmbH develops and supplies healthcare products and solutions, with a focus on diagnostics, diabetes-care systems, cardiovascular (heart and vascular) therapies and medical nutrition.

abc biopply ag 

Solothurn · Since 2017

The company abc biopply ag is a service provider in the field of Life Sciences, specifically in biomedical research and development. The core activity of the company includes the provision of preclinical CRO (Contract Research Organization) services, the development and implementation of assays, the marketing of licenses and partner products, as well as the provision of service packages for various application areas such as oncology, neurology, hepatology and nephrology.

Abela Pharm GmbH 

Zurich · Since 2018

The core activity of Abela Pharm is the development, manufacture and distribution of dietary supplements and health products, particularly in the areas of weight management, detox and anti-aging. The company focuses on producing products based on natural ingredients that aim to promote the health and well-being of its customers.

Abioniv Sàrl 

Courroux · Since 2023

The core activity of Abioniv is the development and marketing of disinfection solutions and products, particularly for industries, fitness studios, swimming pools, SPAs, hotels and nail studios. The company also offers solutions for private customers. The products include foot disinfectants, hand disinfectants and surface disinfectants. Furthermore, Abioniv provides consulting services to support companies in implementing disinfection measures.

ABJ International Inc. 

Bern · Since 2000

Acadia Pharmaceuticals GmbH 

Basel · Since 2014

The core activity of Acadia Pharmaceuticals is the development, manufacture and marketing of pharmaceuticals, particularly in the field of neuroscience and rare diseases.

Swiss PharmaCan Innovation AG 

Tübach · Since 2018

Accense S.A. 

Basel · Since 2014

The core activity of Accense is the acquisition, development and marketing of pharmaceutical products, in particular those abandoned by large pharmaceutical companies. The company focuses on reviving and marketing established, safe and effective medicines that are useful for public health. Products include Postafen, Agyrax and Navidoxine, which are distributed in various countries such as France, Scandinavia, Malta and the USA.

Accord Healthcare AG 

Bottmingen · Since 2016

The company's core activity is the development, production and distribution of pharmaceuticals, in particular generics, biosimilars and original products, with a focus on the therapeutic areas of oncology, autoimmunity/rheumatology and CNS.

acovos AG 

Allschwil · Since 2017

The core activity of Acovos is to provide high-quality, well-characterized human tissue samples for the pharmaceutical and biotechnology industries. In particular, Acovos offers a comprehensive collection of formalin-fixed, paraffin-embedded (FFPE) tissue samples, including tumor, inflammatory, degenerative and normal tissues, as well as matching tissue pairs and tissue samples tested for specific antibodies. These samples are used for the development of drugs and diagnostic products.

Actelion Pharmaceuticals Ltd 

Allschwil · Since 1997

ActiMaris AG 

Appenzell · Since 2013

The core activity of ActiMaris AG is the development, manufacture and marketing of medical products, in particular wound healing products and sprays based on natural ingredients, which have a supportive and promoting effect on wound healing.

Adagene AG 

Basel · Since 2020

The core activity of Adagene is the discovery and development of therapeutic antibodies for the treatment of cancer. The company focuses on developing antibodies with novel mechanisms of action (MOAs) and utilizes its own technology platform, which is based on the dynamic precision of antibodies. Adagene develops antibodies for various applications, including cancer immunotherapy, and has partnerships with global companies to leverage its technology and develop new treatment options.